Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bolognese, L.
Right arrow Articles by Angioli, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bolognese, L.
Right arrow Articles by Angioli, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Myocardial damage during percutaneous interventions for non-ST-elevation acute coronary syndromes

Leonardo Bolognese*, Giovanni Falsini, Francesco Liistro and Paolo Angioli

Department of Cardiovascular Diseases, Azienda Ospedaliera Arezzo, Via Pietro Nenni 22, 52100 Arezzo, Italy

* Corresponding author. Tel: +39 0575255529; fax: +39 0575255523. E-mail address: leonardobolognese{at}hotmail.com

The prognostic significance and pathophysiological mechanisms underlying elevations in cardiac enzymes in patients with non-ST-segment elevation acute coronary syndromes (ACS) post-percutaneous coronary intervention (PCI) is a matter of debate. The few available data, derived mainly from sub-analyses of large randomized trials and from small prospective observational studies, suggest that patients with ACS who undergo PCI have an increased risk for procedural myocardial damage which, in turn, is associated with an adverse clinical outcome. Although the pathophysiology of post-PCI myocardial damage is multifactorial, the embolization of debris or calcified plaque material, or exposure of thrombogenic material at intravascular sites seems to play a key role, as shown by mechanistic studies that demonstrate a close relationship between post-procedural enzyme release and abnormal tissue perfusion. Several pre-procedural treatment strategies using antithrombotic therapies have evolved in an attempt to lower the rate of myocardial damage related to the performance of PCI in ACS patients. Major trials that evaluated the use of glycoprotein (GP) IIb/IIIa inhibitors during PCI in patients with ACS have suggested that maximum benefit is obtained in patients with increased troponin levels and in patients undergoing PCI, reducing the incidence of cardiac enzyme release after the procedure. However, a number of lingering unsolved issues concerning which agent should be used and the most appropriate timing and dosage remain to be explored. Mechanistic and clinical findings suggest that an early invasive strategy with upstream GP IIb/IIIa inhibitors may yield more favourable outcomes than downstream strategies.

Key Words: Acute coronary syndromes • GP IIb/IIIa inhibitors • Myocardial damage


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.